临床相关的微生物对利法西明-α耐药性的发展潜力:叙述性审查

Herbert L DuPont1

  • 1School of Public Health and McGovern Medical School, Baylor College of Medicine, Kelsey Research Foundation, University of Texas Health Science Center Houston, Houston, Texas, USA.

PubMed
概括

利法西明-α是一种向肠道的抗生素,由于吸收最小,因此具有良好的安全性. 它的独特作用和低生物可用性可能会降低抗生素耐药性的风险.